Developments of Combretastatin A-4 Derivatives as Anticancer Agents

Title: Developments of Combretastatin A-4 Derivatives as Anticancer Agents

Volume: 18 Issue: 4

Author(s): Y. Shan Shan, J. Zhang, Z. Liu, M. Wang and Y. Dong

Affiliation:

Keywords: Combretastatin A-4, Tubulin inhibitors, Anticancer, Antineoplastic Agents, Structure-Activity Relationships, antiangiogenesis, Combretum caffrum, chromo-somes, mitosis, microtu-bules, apoptosis, colchicine, vinca alka-loid domain, vinblastine, vincristine, Combretastatins, stilbenoid phenol, tubulin polymerization, chemotherapeutic, structure-activity relationship (SAR), human myelogenous leukaemia cell line, phosphate diesters, carcinoma, pinacolylboronate, boronic acid, Ethene Bridge, olefinic bridge, antineoplastic activity, hyperploid

Abstract: Tubulin protein is one of several members of a small family of globular proteins. It offers a potential target for anticancer drug design and development. Combretastatin A-4 (CA-4) is a potent anticancer and antiangiogenesis natural substance isolated from Combretum caffrum. Modifications on the CA-4 structure have led to a great number of novel CA-4 derivatives as potent tubulin inhibitors and high cytotoxic anticancer agents is becoming an interesting field, leading to a breakthrough in the treatment of cancer. In this review, the recent developments of novel CA-4 derivatives via the modifications on the A- and B-ring and the double bond as anticancer agents are discussed.

Cite this article as:

Shan Y. Shan, Zhang J., Liu Z., Wang M. and Dong Y., Developments of Combretastatin A-4 Derivatives as Anticancer Agents, Current Medicinal Chemistry 2011; 18 (4) . https://dx.doi.org/10.2174/092986711794480221